Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study
Endoscopy International Open · 14.04.2026 · 14 (CP)
DOI: 10.1055/a-2820-3721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 14.04.2026. Verfasst von Yuichiro Hirai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organiszation Tokyo Medical Center, Tokyo, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and study aims It is desirable to develop a safe, cost-effective, and easy approach to prevent strictures after esophageal endoscopic submucosal dissection (ESD). We explored use of a novel rebamipide solution, an anti-ulcer drug, as a submucosal injection material for preventing esophageal stricture after ESD.
Methods
In 15 swine, two half-circumferential ESDs were performed at the proximal and distal ends of the middle thoracic esophagus using 2% rebamipide solution or saline (control) as submucosal injection material. Five swine were sacrificed on postoperative days (PODs) 7, 14, and 21, respectively. Follow-up endoscopy was performed weekly until sacrifice. ESD-related outcomes, degree of stricture, and histological characteristics were evaluated.
Results
ESD-related outcomes were similar in both groups, with all post-ESD ulcers epithelialized by POD 14. Mean mucosal constriction rate in the rebamipide and control groups on PODs 14 and 21 were 19.1 ± 7.2% vs. 21.0 ± 6.4% (P= 0.40) and 13.3 ± 6.8% vs. 20.8 ± 6.1% (P = 0.08), respectively. The rebamipide group peaked and showed milder constriction by POD 21, whereas the control group seemed to plateau. Histologically, mean fibrosis thickness in the rebamipide and control groups on days 14 and 21 were 807.0 ± 238.9 µm vs. 972.8 ± 395.1 µm (P = 0.40) and 782.8 ± 281.5 µm vs. 1087.0 ± 476.1 µm (P = 0.13), respectively.
Conclusions
The rebamipide solution showed no statistically significant benefit in preventing post-ESD stricture. However, given the small sample size of this study, further studies are needed to clarify its potential role.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, National Hospital Organiszation Tokyo Medical Center, Tokyo, Japan.
- Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan.
- Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
Zitieren
APA
Hirai, Y., Fujimoto, A., Sasaki, M., Shimoda, M., & Yahagi, N. (2026). Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study. Endoscopy International Open, 14(CP). https://doi.org/10.1055/a-2820-3721
Vancouver
Hirai Y, Fujimoto A, Sasaki M, Shimoda M, Yahagi N. Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study. Endoscopy International Open. 2026;14(CP). doi:10.1055/a-2820-3721
BibTeX
@article{Hirai2026,
author = {Hirai, Yuichiro and Fujimoto, Ai and Sasaki, Motoki and Shimoda, Masayuki and Yahagi, Naohisa},
title = {Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study},
journal = {Endoscopy International Open},
year = {2026},
volume = {14},
number = {CP},
doi = {10.1055/a-2820-3721}
}
EUVIMED